, Tracking Stock Market Picks
Enter Symbol:
Sarepta Therapeutics Inc (SRPT) [hlAlert]


Sarepta Therapeutics Inc (SRPT) downgraded to Hold by Needham

Posted on: Wednesday,  Nov 13, 2013  8:25 AM ET by Needham

Needham rated Hold Sarepta Therapeutics Inc (NASDAQ: SRPT) on 11/13/2013. Previously Needham rated Buy Sarepta Therapeutics
Inc (NASDAQ: SRPT) on 04/22/2013., when the stock price was $33.93. Since then, Sarepta Therapeutics Inc has lost 62.13% of its value until Needham rated SRPT Buy on 11/13/2013, when the price was $12.85. .

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/2/2015 3:25 PM Buy
38.89 55.00
as of 12/13/2013
1 Week   
1 Month down  -0.31 %
3 Months down  -65.46 %
1 YTD down  -62.12 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/2/2015 8:25 AM Buy
13.88 38.00
1/21/2014 8:25 AM Buy
28.02 36.00
11/13/2013 8:25 AM Hold
4/22/2013 8:25 AM Buy
33.93 57.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy